Modern pharmacotherapy of psoriatic arthritis
https://doi.org/10.14412/1995-4484-2019-75-82
Abstract
About the Authors
Yu. L. KorsakovaRussian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. V. Korotaeva
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Scarpa R, Altomare G, Marchesoni A, et al. Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol. 2010;24:627-30. doi: 10.1111/j.1468-3083.2010.03574.x
2. Smolen J, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017;0:1-15. doi: 10.1136/Ann Rheum Dis-2017-211734
3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5
4. Gossec L, Smolen, J, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12. doi: 10.1136/annrheumdis-2011-200350
5. Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27:1022-5. doi: 10.1111/j.1468-3083.2012.04656.x
6. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2018. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2018. 464 p. (In Russ.)].
7. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28:S132-7.
8. Clegg D, Reda D, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veteran's affairs cooperative study. Arthritis Rheum. 1999;42:2325-9. doi: 10.1002/1529-0131(199911)42:11<2325::AIDANR10>3.0.CO;2-C
9. Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol. 1998;25:1957-61.
10. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238-49. doi: 10.1159/000091251
11. Sakellariou G, Sayegh F, Anastasilakis A, et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int. 2013;33:2917-20. doi: 10.1007/s00296-012-2534-x
12. Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013;65:464-70. doi: 10.1002/acr.21848
13. Curtis J, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69:43-7. doi: 10.1136/ard.2008.101378
14. Fraser A, van Kuijk A, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64. doi: 10.1136/ard.2004.024463
15. Karanikolas G, Koukli E, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38:2466-74. doi: 10.3899/jrheum.110242
16. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90. doi: 10.1016/j.bcp.2012.01.001
17. Корсакова ЮЛ, Денисов ЛН. Эффективность и безопасность нового препарата для лечения псориаза и псориатического артрита – апремиласта. Научно-практическая ревматология. 2016;54(5):572-7 [Korsakova YuL, Denisov LN. The efficacy and safety of the new drug apremilast for the treatment of psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):572-7 (In Russ.)]. doi: 10.14412/1995-4484-2016-572-577
18. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013-205056
19. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Long-term (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479-88. doi: 10.3899/jrheum.140647
20. Mease PJ, Adebajo AO, Gladman DD. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial and open-label extension [abstract]. Arthritis Rheum. 2014;66 Suppl 10:1564.
21. Cutolo M, Myerson GR, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724-34. doi: 10.3899/jrheum.151376
22. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065-73. doi: 10.1136/annrheumdis-2015-207963
23. Wells A, Edwards C, Adebajo AO. Long-term (104-week) safety and efficacy of monotherapy with apremilast in DMARD-naХve patients with psoriatic arthritis: a phase 3, randomized, controlled trial and open-label extension (PALACE 4) [abstract]. Arthritis Rheum. 2014;66 Suppl. 10:L22.
24. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537-50. doi: 10.1056/NEJMoa1615975
25. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377:1525-36. doi: 10.1056/NEJMoa1615977
26. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90. doi: 10.1016/S0140-6736(00)02530-7
27. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72. doi: 10.1002/art.20335
28. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-21.
29. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147. doi: 10.1136/bmj.c147
30. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869-76.
31. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degreeof clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498-505. doi: 10.1136/ard.2006.058339
32. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-8. doi: 10.1136/ard.2011.152223
33. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-9. doi: 10.1136/ard.2008.092767
34. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J Rheumatol. 2007;34:1040-50.
35. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a longterm extension of the randomised, placebo-controlled GOREVEAL study. Ann Rheum Dis. 2013;72:1777-85. doi: 10.1136/annrheumdis-2012-202035
36. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689-94. doi: 10.1136/annrheumdis-2013-204902
37. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55. doi: 10.1136/annrheumdis-2013-203696
38. Van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233-7. doi: 10.1136/annrheumdis-2013-203697
39. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40. doi: 10.1016/S0140-6736(09)60140-9
40. McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT I Study Group: Efficacy and safety of Ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet. 2013;382:780-9. doi: 10.1016/S0140-6736(13)60594-2
41. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000-6. doi: 10.1136/annrheumdis-2013-204741
42. Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi: 10.1002/acr.22645
43. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990-9. doi: 10.1136/annrheumdis-2013-204655
44. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329-39. doi: 10.1056/NEJMoa1412679
45. Van der Heijde D, Landewe RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheum. 2016;68:1914-21. doi: 10.1002/art.39685
46. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015;386:1137-46. doi: 10.1016/S0140-6736(15)61134-5
47. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:52. doi: 10.1186/ar2670
48. Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exper Rheumatol. 2017;35:991-1010.
49. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014;53(8):1377-85. doi: 10.1093/rheumatology/ket409
50. Sieper J, van der Heijde DM, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784-8. doi: 10.1136/ard.2008.101501
51. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978-91. doi: 10.1136/annrheumdis-2016-210770
52. Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis. Arch Dermatol. 2012;148:1403-10. doi: 10.1001/2013.jamadermatol.238
53. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-38. doi: 10.1056/NEJMoa1314258
Review
For citations:
Korsakova Yu.L., Korotaeva T.V. Modern pharmacotherapy of psoriatic arthritis. Rheumatology Science and Practice. 2019;57(1):75-82. (In Russ.) https://doi.org/10.14412/1995-4484-2019-75-82